ABSSSIs
A Branded Antibiotic May Be Cost-Effective
When acute bacterial skin and skin structure infections are not cured by oral antibiotics, many health systems opt ...
DECEMBER 23, 2024
Use of Dalbavancin in Optimizing the Management of ABSSSIs in Patients With Obesity or Diabetes
This Special Report reviews data on the use of dalbavancin for the treatment of ABSSSIs to support safety and ...
JULY 9, 2024
Reducing the Economic Burden of Hospital Admissions in Treating Patients With ABSSSIs
This Special Report reviews the clinical and economic challenges of acute bacterial skin and skin structure ...
FEBRUARY 1, 2024
FDA Grants Pediatric Indication for Dalvance
The FDA granted a new indication to dalbavancin for the treatment of acute bacterial skin and skin structure ...
JULY 26, 2021
FDA Committee Recommends Approval of Omadacycline
The FDA Antimicrobial Drugs Advisory Committee voted in favor of the approval of IV and oral omadacycline (Paratek ...
AUGUST 10, 2018
